Table 1. Summary of patient and treatment characteristics (N=85).
| Parameter | No. (%) |
|---|---|
| Age (years) at the SRT | |
| Median (range) | 59 (32-89) |
| Gender | |
| Male | 54 (64) |
| Female | 31 (36) |
| Primary tumors | |
| Non-small cell lung cancer | 53 (62) |
| Esophageal carcinoma | 7 (8) |
| Breast cancer | 7 (8) |
| Hepatocellular carcinoma | 3 (4) |
| Thyroid carcinoma | 3 (4) |
| Kidney cancer | 3 (4) |
| Bladder cancer | 2 (2) |
| Thymic carcinoma | 1 (1) |
| Nasopharyngeal cancer | 1 (1) |
| Ovarian cancer | 1 (1) |
| Rectal cancer | 1 (1) |
| Cervical cancer | 1 (1) |
| Sublingual adenocarcinoma | 1 (1) |
| Submandibular gland cancer | 1 (1) |
| No. of MLNs within LN zone | |
| 1 | 72(85) |
| 2 | 13 (15) |
| Clinical symptoms of MLNs | |
| Yes | 53 (62) |
| No | 32 (38) |
| Radiographic diagnosis of MLNs | |
| PET-CT | 64 (75) |
| CT | 21 (25) |
| Synchronous metastases | |
| Yes | 37 (44) |
| No | 48 (25) |
| Interval between the diagnosis of primary and SRT (median, in months) | |
| < 21.23 | 49 (58) |
| ≥ 21.23 | 36 (42) |
| History ofRT (overlap of the present lesions with the field of RT) | |
| Yes | 29 (34) |
| No | 56 (66) |
| SRT treatment intent | |
| Curative | 83 (98) |
| Palliative | 2 (3) |
| Other treatments after SRT | |
| Chemotherapy | 37 (48) |
| Endocrine therapy† | 3 (4) |
| Molecular targeted therapy‡ | 9 (11) |
†
Three breast cancer patients with positive of ER, PR, and Her-2 received endocrine therapy.
‡
Seven lung adenocarcinoma patients with EGFR mutation received erlotinib or gefitinib, and 2 hepatocellular carcinoma received sorafenib.
Abbreviations: MLNs: mediastinal lymph nodes; PET-CT: positron emission tomography/computed tomography; CT: computed tomography; SRT: stereotactic radiation therapy; RT: radiotherapy.